About ReCode Therapeutics
ReCode Therapeutics develops gene therapy solutions aimed at treating complex respiratory diseases, specifically cystic fibrosis and primary ciliary dyskinesia. Their approach involves utilizing advanced drug development techniques to create therapies that can effectively target and restore function in patients suffering from these conditions. Unlike many competitors, ReCode Therapeutics emphasizes rapid advancement through a deep understanding of regulatory pathways and clinical trial processes. The company's goal is to overcome challenges in delivering therapies directly to affected areas in the lungs, ultimately enhancing the quality of life for patients with unmet medical needs.
Dallas, TexasHeadquarters
2015Year Founded
$338MTotal Funding
GRANTCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees
Benefits
Health Insurance
401(k) Company Match
Paid Holidays
Mental Health Support
Health Savings Account/Flexible Spending Account
Employee Discounts
Risks
Competition from Vertex Pharmaceuticals in the CF space is significant.
Scaling SORT LNP platform for commercial use may face manufacturing challenges.
Regulatory hurdles for gene editing therapies could delay approvals.
Differentiation
ReCode's SORT LNP platform enables precise delivery beyond the liver.
Focus on respiratory diseases like CF and PCD sets ReCode apart in gene therapy.
Strategic collaboration with Intellia enhances ReCode's CRISPR-based gene editing capabilities.
Upsides
$15M investment from CF Foundation boosts ReCode's gene editing therapy development.
Phase 1 study of RCT2100 marks progress in inhaled mRNA therapies for CF.
Experienced leadership with Dean J. Mitchell strengthens ReCode's strategic direction.
Funding
Total raised$338.02 M
Latest valuation$600.00 M
StageGRANT
GRANT
10/31/2024$15
SERIES B
8/31/2023$50
$600.00 MSERIES A
2/29/2020$80
$400.00 MSEED
1/31/2019$2
$10.00 M